Of note, we found patients with COVID-19 who were treated with CGRP mAbs were more likely to report mild symptoms (abdominal pain and sore throat), but there were no significant differences in moderate symptoms such as dyspnea.32 One possible explanation is that receipt of a CGRP mAb is associated with a more positive health belief; 3 failures of conventional preventatives may not change patients’ perceptions so that they are more likely to react to cues when they experience COVID-19 symptoms. This evidence concerns the gene CALCA and COVID-19.